R&D channel feed

Sang­amo's sick­le cell al­liance with Sanofi grinds to a halt as phar­ma gi­ant switch­es fo­cus to al­lo

4 years ago

In new post-Mer­ck role, Roger Perl­mut­ter rakes in half a bil­lion dol­lars to change the way sci­en­tists look at pro­teins

4 years ago

Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

4 years ago
People

Clover Bio­phar­ma­ceu­ti­cals sets up a new R&D cen­ter in a buzzy Chi­nese hub near Shang­hai

4 years ago
China
Manufacturing

Avro­bio halts PhII study for Fab­ry dis­ease in an­oth­er set­back, shut­ter­ing lead pro­gram

4 years ago

No­vavax breaks an­oth­er pledge for its Covid-19 vac­cine. And the US is re­port­ed­ly fret­ting about glob­al goals now

4 years ago

Not every­body is buy­ing it, but every­body is def­i­nite­ly talk­ing about a new Bio­gen buy­out re­port

4 years ago

Bridge­Bio shares go in­to melt­down mode as their lead PhI­II drug im­plodes at the fin­ish line

4 years ago

No­var­tis taps Roche's neu­ro and rare dis­ease re­search lead to run neu­ro­science re­search

4 years ago
People

Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

4 years ago

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

4 years ago
Cell/Gene Tx
In Focus

Bil­lion­aire Bob Dug­gan's new an­tibi­ot­ic play fails a Phase III tri­al, and in­vestors aren't hap­py

4 years ago

FDA slams clin­i­cal hold on tiny psy­che­delics play­er's shot at bring­ing LSD-as­sist­ed ther­a­py to more pa­tients

4 years ago
FDA+

Eli Lil­ly shep­herds its $1.1B con­tender through an­oth­er PhI­II chal­lenge on the way to the FDA

4 years ago

Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

4 years ago
FDA+

One of Pfiz­er’s Duchenne gene ther­a­py tri­als put on hold in wake of pa­tient death as high-dose AAV con­cerns still cloud field

4 years ago
Cell/Gene Tx
FDA+

Blue­bird shares tank af­ter FDA puts an­oth­er hold on its long de­layed sick­le cell gene ther­a­py

4 years ago
FDA+

Roche, Genen­tech tap re­gen­er­a­tive cell ther­a­py play­er for drug col­lab­o­ra­tion in eye dis­ease

4 years ago

Weeks af­ter earn­ing CEO's stamp of ap­proval, a No­var­tis skin drug los­es head-to-head bat­tle with stan­dard of care

4 years ago
Pharma

FDA hands As­traZeneca-Am­gen broad ap­proval for asth­ma an­ti­body, clear­ing block­buster path

4 years ago
Pharma

Truce: Mod­er­na backs down in patent fight with NIH as it touts ear­ly boost­er da­ta against Omi­cron

4 years ago
Coronavirus

Days af­ter buy­out news, Vi­for out­lines plan to of­fload 'non-core' fin­ished drug man­u­fac­tur­ing wing

4 years ago
Manufacturing

IN8bio's 'off-the-shelf' gam­ma delta T cells stave off re­lapse for high-risk leukemia pa­tients in very ear­ly da­ta cut

4 years ago
Cell/Gene Tx

Un­co­or­di­nat­ed and re­dun­dant: FDA's Paz­dur slams check­point in­hibitor de­vel­op­ers for cre­at­ing a 'Wild West'

4 years ago
China
FDA+
First page Previous page 150151152153154155156 Next page Last page
A service from the Financial Times